![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Hyperbaric Systems is sold on the OTC exchange. The company's vision is to extend the shelf life of blood platelets from the current 5 day mark to 13 days with their preservation technology of drastically lowering the temperature which decreases bacteria formation time thereby extending the shelflife of blood platelets. The company is currently in development stage and testing right now but plans on completion of their validation tests within the next 90 days and will start infusion in the same period. There is exceptional market potential for this product because of blood shortages nationwide. If the technology pans out the company also plans on integrating the technology to organs as well which could mean mega bukoo bucks especially when you consider that if they could extend the life of a heart after withdrawn from the donor from 5 hours to lets say a day. Of course this is all speculation at this point but think of the lives the technology could save and the company is currently selling at $1.05 a share. What a bargain in the risk reward tradeoff.
| ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |